What is Zacks Research’s Forecast for ENSC FY2027 Earnings?

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Analysts at Zacks Research issued their FY2027 EPS estimates for Ensysce Biosciences in a research report issued on Tuesday, March 31st. Zacks Research analyst B. Sorensen expects that the company will post earnings of ($0.20) per share for the year. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Ensysce Biosciences Trading Up 1.6%

Shares of ENSC opened at $0.55 on Wednesday. The stock’s 50 day moving average is $0.54 and its two-hundred day moving average is $1.32. Ensysce Biosciences has a twelve month low of $0.31 and a twelve month high of $4.85. The firm has a market capitalization of $1.99 million, a PE ratio of -0.13 and a beta of 1.12.

Ensysce Biosciences (NASDAQ:ENSC) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.51. The business had revenue of $1.88 million for the quarter, compared to analyst estimates of $0.50 million. Ensysce Biosciences had a negative net margin of 200.87% and a negative return on equity of 458.65%.

Institutional Trading of Ensysce Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. TRU Independence Asset Management 2 LLC acquired a new stake in shares of Ensysce Biosciences in the third quarter valued at approximately $25,000. Virtu Financial LLC acquired a new position in shares of Ensysce Biosciences during the 3rd quarter worth approximately $34,000. Citadel Advisors LLC purchased a new stake in Ensysce Biosciences in the 3rd quarter valued at approximately $34,000. DRW Securities LLC lifted its stake in Ensysce Biosciences by 42.4% in the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after buying an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its holdings in Ensysce Biosciences by 100.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after buying an additional 75,000 shares during the last quarter. Hedge funds and other institutional investors own 5.63% of the company’s stock.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.